GHA
BIIB icon

GW Henssler & Associates’s Biogen BIIB Stock Holding History

GW Henssler & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-826
Closed -$235K – 214
2023
Q2 		$235K Sell
826
-400
-33% -$119K 0.02% 178
2023
Q1 		$341K Buy
1,226
+10
+0.8% +$2.77K 0.02% 146
2022
Q4 		$337K Hold
1,216
– – 0.02% 144
2022
Q3 		$325K Buy
1,216
+184
+18% +$39.1K 0.02% 130
2022
Q2 		$210K Buy
+1,032
New +$211K 0.02% 204

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GW Henssler & Associates's BIIB Position: Q3 2023 in Review

GW Henssler & Associates sold out of Biogen (BIIB) in Q3 2023, closing a stake of 826 shares — an estimated $235K sold.

GW Henssler & Associates first reported a position in BIIB in Q2 2022 and held it in 5 quarters. The position peaked at $341K in Q1 2023. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

  • GW Henssler & Associates reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
  • GW Henssler & Associates sold 826 Biogen shares in Q3 2023, an estimated $235K.
  • GW Henssler & Associates first reported a position in Biogen in Q2 2022 and held it in 5 quarters.
  • GW Henssler & Associates's Biogen position peaked at $341K in Q1 2023.
  • 965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on GW Henssler & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.